{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Wound Bed Preparation 2024: Delphi Consensus on Foot Ulcer Management in Resource-Limited Settings
Activity Steps
Description
AUTHORS: Smart, Hiske MA, RN, PG Dip (UK); Sibbald, R. Gary MD, Med, FRCPC (Med Derm), FAAD, MAPWCA, JM; Goodman, Laurie MHScN, RN; Ayello, Elizabeth A. PhD, RN, CWON, ETN, MAWPCA, FAAN; Jaimangal, Reneeka MD, MDcCH; Gregory, John H. BEng; Akita, Sadanori MD, PhD; Alavi, Afsaneh MD, FRCPC; Armstrong, David G. DPM, MD, PhD; Arputhanathan, Helen MSc, RN, NSWOC, WOCC(C); Bruwer, Febe PhD (UFS), MSocSci, MSc; Caul, Jeremy MClSc-WH, RN, WOCC(c); Chan, Beverley MD, MSc, FRCSC; Cronje, Frans MBChB, MSc; Dofitas, Belen MD, PhD; Hamed, Jassin MD; Harley, Catherine eMBA, RN; Heil, Jolene MCISc-WH, RN, NSWOC; Hill, Mary MN, BScN, RN, NSWOC, WOCC(C), NSWOC; Jahnke, Devon DCh, McISc-WH; Kalina, Dale MD, MBA, FRCPC (ID); Kodange, Chaitanya MBBS, DMM, DHA, MD (Psy); Kotru, Bharat PhD, MSc, DPM; Kozody, Laura Lee DCh; Landis, Stephan MD, FRCPC; LeBlanc, Kimberly PhD, RN, NSWOC, WOCC(C), FCAN; MacDonald, Mary MD, PhD, FRCSC; Mark, Tobi BSc, DCh; Martin, Carlos DM, PG-Dip, MBBS; Mayer, Dieter MD, FAPWCA; Murphy, Christine PhD, MClSc-WH, RN, NSWOC, WOCC(C); Nair, Harikrishna MD, PhD, FRCPI, FRCPE, FCWCS; Orellana, Cesar MD, FRCPC, FACP; Ostrow, Brian MD, BSc, FRCS(C); Queen, Douglas PhD, MBA; Rainville, Patrick DCh; Rajhathy, Erin MclSc-WH, RN, NSWOC, WOCC(C); Schultz, Gregory PhD; Somayaji, Ranjani MD, MPH, FRCPC; Stacey, Michael C. DS, MBBS, FRACS; Tariq, Gulnaz MSc (UK), RN, PG Dip (PAK); Weir, Gregory MBChB, Mmed (Ch); Whiteside, Catharine MD, PhD, CM FRCPC; Yifter, Helen MD; Zacharias, Ramesh MD, FRCS(C)Learning Objectives
After completing this continuing education activity you will be able to:
- Summarize issues related to wound assessment.
- Identify a class of drugs for the treatment of type II diabetes mellitus that has been shown to improve glycemia, nephroprotection, and cardiovascular outcomes.
- Synthesize strategies for wound management, including treatment in resource-limited settings.
- Specify the target time for edge advancement in chronic, healable wounds.
Learning Outcomes
By the conclusion of this activity, a majority of the participants will demonstrate knowledge of a practical and scientifically sound application of the wound bed preparation model for communities without ideal resources by achieving a passing score on the posttest.Disclosures
Dr. Alavi is a consultant for Abbvie, Boehringer Ingelheim, InflaRx, Incyte, Novartis, UCB, and Kymera; Dr. LeBlanc is on the speakers board for Mölnlycke Health Care, Urgo, Medline, and 3M; Dr Murphy is a speaker for 3M, Convatec, and Urgo Medical and a member of advisory boards for Convatec and Urgo Medical; Dr. Somayaji has received advisory board honoraria from Vertex pharmaceuticals; Dr Stacey is a clinical and research advisor for Sterasure Inc; Dr. Sibbald is a consultant for Perfuse Medtech and Novartis; Dr. Schultz is a board member at QuickMed Technologies, a consultant for Bactiguard and NOxy, and is a paid lecturer for Urgo. All other authors, faculty, staff, and planners have disclosed no relevant financial relationships with any ineligible organizations. Lippincott CME institute has identified and mitigated all relevant financial relationships.
Credits:
- ANCC 4.0 CH
- DC - BON 4.0 CH
- FL - BON 4.0 CH
- GA - BON 4.0 CH
- NM - BON 4.0 CH
- SC - BON 4.0 CH
- WV - BOERN 4.0 CH